-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC announced that it has received a $25 million R&D milestone payment from AstraZeneca on July 10, 2026. Previously, the company received the down payment under the agreement on May 29, 2026. The agreement aims to develop innovative long-acting peptide drugs using CSPC Group's long-term delivery technology platform and peptide drug AI discovery platform.

Zhitongcaijing·07/10/2026 14:33:14
Listen to the news
CSPC announced that it has received a $25 million R&D milestone payment from AstraZeneca on July 10, 2026. Previously, the company received the down payment under the agreement on May 29, 2026. The agreement aims to develop innovative long-acting peptide drugs using CSPC Group's long-term delivery technology platform and peptide drug AI discovery platform.